Male Urogenital Diseases
14
7
8
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
7%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (14)
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures
The Radium-select Study
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
Intraoperative Nerve Monitoring During Robotic-assisted Radical Prostatectomy
Office Based Transperineal Laser Ablation for Benign Prostatic Hyperplasia HYPERPLASIA
Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor
Early Oxybutinin Treatment for Boys With Posterior Urethral Valves
Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia
Comparison of Gas Consumption From Two Different Anesthesia Machines